Gene Therapy Market by Vector Type, and Applications - Global Opportunity Analysis and Industry Forecast, 2017-2023 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The “Gene Therapy Market by Vector Type, and Applications - Global Opportunity Analysis and Industry Forecast, 2017-2023” report has been added to ResearchAndMarkets.com’s offering.
The global gene therapy market was valued at $584 million in 2016, and is estimated to reach $4,402 million by 2023, registering a CAGR of 33.3% from 2017 to 2023
Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patients cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools.
For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.
The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market.
DriversHigh investment for R&D activities pertaining to gene therapy Increase in prevalence of cancer Growth in awareness regarding gene therapy
RestraintsHigh cost associated with gene therapies Unwanted immune responses
OpportunityUntapped potential for emerging markets
KEY MARKET SEGMENTS
By Vector TypeViral vector Retroviruses Lentiviruses Adenoviruses Adeno Associated Virus Herpes Simplex Virus Poxvirus Vaccinia Virus Others Non-viral vector Naked/Plasmid Vectors Gene Gun Electroporation Lipofection Others
By Gene TypeAntigen Cytokine Tumor Suppressor Suicide Deficiency Growth factors Receptors Others
By ApplicationOncological Disorders Rare Diseases Cardiovascular Diseases Neurological Disorders Infectious disease Other Diseases
KEY PLAYERS PROFILEDNovartis Kite Pharma, Inc. GlaxoSmithKline PLC Spark Therapeutics Inc. Bluebird bio Inc. Genethon Transgene SA Applied Genetic Technologies Corporation Oxford BioMedica NewLink Genetics Corp.
For more information about this report visit https://www.researchandmarkets.com/research/gknz9f/gene_therapy?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005435/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH GENETICS
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/11/2018 05:10 AM/DISC: 06/11/2018 05:10 AM